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Abstract
Background: Human metapneumovirus (HMPV) is an important respiratory pathogen that causes seasonal
epidemics of acute respiratory illness and contributes significantly to childhood pneumonia. Current knowledge and
understanding on its patterns of spread, prevalence and persistence in communities in low resource settings is
limited.
Methods: We present findings of a molecular-epidemiological analysis of nasal samples from children < 5 years of
age admitted with syndromic pneumonia between 2007 and 2016 to Kilifi County Hospital, coastal Kenya. HMPV
infection was detected using real-time RT-PCR and positives sequenced in the fusion (F) and attachment (G) genes
followed by phylogenetic analysis. The association between disease severity and HMPV subgroup was assessed
using Fisher’s exact test.
Results: Over 10 years, 274/6756 (4.1%) samples screened were HMPV positive. Annual prevalence fluctuated
between years ranging 1.2 to 8.7% and lowest in the recent years (2014–2016). HMPV detections were most
frequent between October of one year to April of the following year. Genotyping was successful for 205/274
(74.8%) positives revealing clades A2b (41.0%) and A2c (10.7%), and subgroups B1 (23.4%) and B2 (24.9%). The
dominance patterns were: clade A2b between 2007 and 11, subgroup B1 between 2012 and 14, and clade A2c in
more recent epidemics. Subgroup B2 viruses were present in all the years. Temporal phylogenetic clustering within
the subgroups for both local and global sequence data was seen. Subgroups occurring in each epidemic season
were comprised of multiple variants. Pneumonia severity did not vary by subgroup (p = 0.264). In both the F and G
gene, the sequenced regions were found to be predominantly under purifying selection.
Conclusion: Subgroup patterns from this rural African setting temporally map with global strain distribution,
suggesting a well-mixed global virus transmission pool of HMPV. Persistence in the local community is
characterized by repeated introductions of HMPV variants from the global pool. The factors underlying the
declining prevalence of HMPV in this population should be investigated.
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Background
Human metapneumovirus (HMPV) is single-stranded,
negative-sense RNA virus with a genome of about 13 kb
[1, 2]. The virus belongs to the Pneumoviridae family
and genus Metapneumovirus. HMPV infections occur
across all ages with severe disease predominantly occur-
ring in children below 2 years of age and the elderly [3–
5]. Since first description in 2001 [5], HMPV has been
detected in all continents and its disease prevalence var-
ies widely [6]. Nearly every child by the age of 5 years
has been infected by HMPV [5, 7]. Clinical presentation
of HMPV infection ranges from mild upper respiratory
tract illness to severe lower respiratory tract disease [8]
and overlaps with that of other common respiratory vi-
ruses especially respiratory syncytial virus (RSV) [9, 10].
HMPV is classified into two major groups, A and B,
based on antigenic variation and nucleotide differences
in the fusion (F), nucleoprotein (N) and attachment (G)
glycoprotein genes [2, 11, 12]. Phylogenetic analyses of F
(open reading frame, i.e. ORF) and G (ORF) sequences
further divides the two groups into subgroups i.e. A1
and A2 (group A), and B1 and B2 (group B) subgroups
[11, 13]. In addition, there has been report of within
subgroup A2 division, i.e. presence of two phylogenetic-
ally distinct clades A2a and A2b [14]. A few studies have
revealed increased heterogeneity of A2, including identi-
fication of another distinct clade, provisionally assigned
as A2c [15, 16]. Furthermore, two novel clades within
subgroup A2 with 180 or 111 nucleotide duplications in
the G gene have been detected [17–20]. Geographically,
HMPV subgroups have been reported to circulate widely
and cluster temporally [21], with the exception of sub-
group A1 that has been identified in a few countries
[21–23]. There is frequent co-circulation of subgroups
with replacement of the predominant subgroup after a
period of one or two seasons, although the drivers of this
phenomena are unclear [21]. Virus prevalence also varies
from year-to-year within the same location [24, 25].
A few studies have reported long-term subgroup circu-
lation patterns of HMPV, necessary for improved epi-
demiological understanding and, in due course, of
potential value to the design and implementation of con-
trol measures. In addition, there are a few studies on
HMPV in Africa, which bears a high burden of pneumo-
nia morbidity and mortality [26, 27]. In this study, we
analysed the surface F and G gene nucleotide sequences
collected through paediatric pneumonia surveillance at
the Kilifi County Hospital in rural coastal Kenya, from
2007 to 2016, to describe the molecular epidemiology
and gain insights into the spread and the evolutionary
dynamics of HMPV. The two genes (F and G) code for
immunogenic surface proteins that are the targets for
vaccine development. G gene is highly variable and is
used to assess the diversity of HMPV. Similarly, F gene
which is quite conserved, has been used to characterise
HMPV and is the gene of target in many molecular
diagnostic assays. This report extends our previously
published work from the same location for the period
2007–11 [28] and the analysis includes sequences from
this previous work.
Methods
Study population
The study was conducted at the Kilifi County Hospital
(KCH) as part of long-term surveillance aimed at
understanding the epidemiology and disease burden of
RSV-associated pneumonia cases [29]. KCH, located in
coastal Kenya, is a referral hospital serving the popula-
tion of around 260,000 (circa 2012) within the Kilifi
Health and Demographic Surveillance System [30], and
beyond in the wider Kilifi County. The population is
mainly rural-agrarian. Upon presentation of a child to
the paediatric ward at KCH, a detailed medical review is
undertaken by the clinician upon which the decision to
admit is made. For this study, children (≤ 59 months of
age) admitted to the paediatric ward between January
1st 2007 and December 31st 2016 were eligible if they
presented with modified WHO defined syndromic severe
or very severe pneumonia as previously described [29].
During the period between 2007 and 2009, only admis-
sions arising from residents of Kilifi Health and Demo-
graphic Surveillance System (KHDSS) were eligible,
whereas in later years, non-KHDSS residents were in-
cluded. Following written informed consent from the
parent or guardian, a nasopharyngeal flocked swab, nasal
wash or combination of nasopharyngeal swab and oro-
pharyngeal swab was collected from each child and
transferred into viral transport medium for laboratory
screening. Ethical approval for the study was obtained
from the Kenya Medical Research Institute Scientific
and Ethics Review Unit.
RNA extraction and rRT-PCR
For samples collected from 2007 to 2011 the methods
for extraction and detection were as previously described
[31, 32]. In brief, for samples collected in 2007 RNA was
extracted using Magnapure LC32 total nucleic acid ex-
tractor (Roche, Manheim, Germany) and virus screening
conducted using the LightCycler Fast Start DNA Mas-
terPLUS Hyb-Probe kit (Roche, Mannheim, Germany)
following manufacturer’s instructions. From 2008 to
2011, sample extraction was by MagNaPure LC32 Kit
(Roche, Manheim, Germany) or QIAmp Viral RNA
Minikit (Qiagen, Germany) and virus detection carried
out using a one-step in-house multiplex real time re-
verse transcription-PCR (rRT-PCR) using a TaqMan
probe-based system targeting the fusion (F) gene [28,
32]. Samples with a rRT-PCR cycle threshold (Ct) value
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< 35 were considered HMPV positive. From 2012 to
2016 total RNA extraction was performed using Qia-
cube HT automated total nucleic acid extractor (Qia-
gen, Germany) and virus detection carried out using
the same one-step in-house multiplex real time reverse
transcription-PCR (rRT-PCR) used for samples from
2008 to 11 [28].
F and G gene sequencing
HMPV positive samples identified between 2007 and
2011 (n = 160) were partially sequenced in the F and G
genes, 345 and 606 bp, respectively [28]. For HMPV
positive samples identified between 2012 and 2016 (n =
114), we amplified full F and G encoding genes, approxi-
mately 1620 bp and 700 bp, respectively, using one-step
RT-PCR kit (Qiagen, Germany) according to manufac-
turer’s instructions. RT-PCR and sequencing primers are
shown in Additional file 1. Thermocycling conditions for
both genes were set at: 50 °C for 30 min, 95 °C for 15
min, 38 cycles of 94 °C for 1 min, 53 °C for 1 min,
72 °C for 1 min, and a final extension of 10 min at
72 °C. HMPV A and B subtype specific primers were
used to increase the sensitivity and the performance
of G gene amplification. HMPV positive samples were
sequenced in both forward and reverse directions
using Big dye terminator v1.3 chemistry run on ABI
3130xl instrument [33].
Sequence analysis and diversity
Sequence reads for the successfully amplified HMPV
positives identified between 2012 to 2016 were edited
and assembled using Sequencher v5.0.1 (Gene Codes
Corporation). The newly assembled F and G genes se-
quences were deposited in GenBank under accession
numbers MH482553 to MH482743. The accession num-
bers (MH482553 to MH482743) include additional 31
sequences that were detected by different rRT-PCR assay
and therefore they were excluded in this analysis. The
accession numbers for the excluded sequences (15 for F
gene and 16 for G gene) are given in Additional file 2.
For subsequent analyses, previously sequenced data for
HMPV positives identified between 2007 and 2011 i.e. F
(n = 123) and G (n = 56) genes [28] (accession numbers
KT191299 to KT191484) was combined with the newly
sequenced data, making a total of 210 sequences for F
gene and 118 sequences for G gene used in subsequent
analyses. Sequences were aligned with MAFFT v7.220
[34]. Nucleotide and amino acid mean genetic dis-
tances within and between subgroups were deter-
mined using Kimura-2 parameter model in MEGA v7.
0.2.6 [35]. Further, to assess sequence diversity within
epidemics, collated G gene sequences were aligned by
epidemic sampling to show changes in the G gene
within epidemics.
Phylogenetic analysis
Contemporaneous sequences (2007 to 2016) were ob-
tained from GenBank for both F and G genes. Sequences
had to have a complete overlap in their sequenced por-
tion with the Kilifi sequence data. Duplicate sequences
were dropped. A total of 714 F gene sequences and 500
G sequences were retrieved. For phylogenetic construc-
tion, sequences were filtered per country using an
inhouse ruby script to obtain only unique sequences.
Unique sequences were identified as sequences that dif-
fer by at least one nucleotide from any other sequence
over the sequenced region. Combined global and Kilifi
sequences were aligned using MAFFT v7.220. Best fit-
ting nucleotide substitution and site heterogeneity
models were estimated in MEGA v7. 0.2.6 and phylogen-
etic trees inferred using Maximum Likelihood (ML) with
1000 bootstrap replicates. Reference sequences from
GenBank (FJ168778 NL/94/01/B2, AY525843 HMPV
NL/1/99/B1, AF371337 HMPV NL/1/00/A1, AB503857,
AY530095 HMPV JP/240/03/A2b and GQ153651
HMPV CN/gz01/08/A2) were included [36]. A fragment
length of 345 bp was analysed for F gene and at least
640 bp for G gene. Subgroups were confirmed if se-
quences clustered with the reference sequences within a
major branch with > 70% bootstrap support on the ML
tree. Mean nucleotide genetic distances were also deter-
mined to assess sequence similarity between Kilifi and
the global data set. To further assess the clustering of
HMPV subgroups, ML tree was reconstructed using only
full F (1593 bp) gene sequences.
Evolutionary and selection pressure analysis of Kilfi HMPV
viruses
Substitution rates and time to the most recent common
ancestor (tMRCA) were determined under uncorrelated
lognormal relaxed molecular clock using Bayesian Mar-
kov Chain Monte Carlo-based approach implemented in
BEAST v1.8.4. Demographic histories of HMPV sub-
groups were inferred using GMRF Bayesian Skyride
model. BEAST analysis was set at 50 million states with
sampling every 2500 steps. Selection pressure within F
and G genes was analysed by estimating the ratios of
non-synonymous to synonymous substitutions (dN/dS =
ω), using the codon-based phylogenetic method
(CODEML) in PAML v 4.8a. Different site models were
employed i.e. M0 (one ratio), M1a (Nearly Neutral), M2a
(Positive Selection) and M3 (discrete) model. M0 model
calculates a rough average value (ω) distributed across
all sites (homogeneous ratios). M1a assumes two cat-
egories of sites: conserved sites with ω = 0 and neutral
sites with ω = 1. M2a allows for three classes i.e. neutral
ω = 1, purifying (0 ≤, ω < 1), and positive selection ω > 1.
M3 estimates ω ratios as M2a but using an uncon-
strained discrete distribution [37, 38]. The models M0
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and M1a were used to test for selection over the entire
sequenced regions while M2a and M3 tested for posi-
tively selected sites. Only sites with posterior probabil-
ities > 95% were considered as positively selected based
on Bayes Empirical Bayes method.
HMPV subgroup and disease severity
Different Kilifi HMPV subgroups identified between 2007
and 2016 were determined. To assess the association
between HMPV subgroup and disease severity, we per-
formed Fisher’s exact test. Individuals were defined syn-
dromically as either severe or very severe based on WHO
definitions [39]. The clinical definitions have been de-
scribed previously [28, 29, 31]. A p-value of ≤ 0.05 was
considered to be significant. Statistical analysis was con-
ducted using STATA v13.1 (College Station Texas, USA).
Results
HMPV prevalence in paediatric hospital admissions
Between January 2007 and December 2016, 9079 indi-
viduals below 60months of age were admitted to the
paediatric wards at KCH with severe or very severe
pneumonia. Samples were collected from 6756 (74%)
individuals and 274 (4.1%) were determined HMPV
positive (Table 1). Decreased HMPV prevalence was re-
corded in more recent years i.e. from 2014 to 2016
(Table 1). Among the 274 HMPV positive cases, 43.1%
(n = 118) were in children < 6months of age and 71.5%
(n = 196) in children < 2 year of age. Children ≥3 years
accounted for only 3.6% of the cases (n = 11) (Table 2).
HMPV subgroup assignment
Phylogenetic analysis (F and G gene) of Kilifi, global and
the reference sequences showed clustering of HMPV
viruses into subgroups A2, B1 and B2. Subgroup A1 was
not observed. Subgroup A2 sequences further clustered
into 3 clades, the two known clades A2a and A2b, and
into the unique clade A2c supported by strong bootstrap
values (Figs. 1 and 2). The recently identified unique
HMPV A2 strain, which possess 180 duplication in G
gene clustered within A2c clade (Fig. 1) and was not ob-
served in the Kilifi sequences. Based on F gene phyl-
ogeny constructed using full length coding regions,
similar clades and sub-groups were also observed i.e.
A2a, A2b, A2c, B1 and B2 (Additional file 3).
The prevalence of group A was 51.7% (106/205) and
group B 48.3% (99/205). All the group A Kilifi sequences
clustered within clade A2b (84/106, 79.2%) and within
the unique clade A2c (22/106, 20.8%). No A1 or A2a se-
quences were observed. Within group B, 48.5% (48/99)
of the sequences clustered within subgroup B1 and
51.5% (51/99) of the sequences clustered within sub-
group B2.
Temporal occurrence of HMPV in Kilifi
During the 10-year period of surveillance described here,
HMPV infections occurred in a seasonal pattern, mainly
between the month of October of one year and April of
the following year, Fig. 3, which was used to define an
epidemic year, i.e. starting September of one year
through August of the following year. Thus, subsequent
analyses were done by epidemic year. Multiple sub-
groups co-circulated within a single epidemic year from
2007 to 2016, Fig. 4b. There was a shift in dominance
from A2b (2007 to 2011) to B1 (2012 to 2014) with sub-
sequent rise of the A2c in recent years. Notably, B2 sub-
groups remained persistent but non-dominant. A2b
viruses circulated only until November 2012.
Table 1 Number of samples tested for HMPV and cases positives per year from 2007 to 16 amongst pneumonia paediatric
admissions to Kilifi County Hospital, Kenya
Year Admissionsa Eligibleb Testedc HMPV Positive HMPV Prevalence (95% CI)
2007 3506 1174 726 21 2.90 (1.80–4.39)
2008 3204 1009 435 34 7.80 (5.47–10.75)
2009 3633 1105 526 46 8.70 (6.47–11.49)
2010 3091 1090 903 27 3.00 (1.98–4.32)
2011 3005 906 730 32 4.40 (3.02–6.13)
2012 2715 863 943 50 5.30 (3.96–6.93)
2013 2074 566 540 28 5.20 (3.47–7.41)
2014 2947 797 695 18 2.60 (1.54–4.06)
2015 3029 793 658 8 1.20 (0.53–2.38)
2016 2803 776 600 10 1.70 (0.80–3.04)
Overall 30,007 9079 6756 274 4.10
Abbreviations: CI Confidence intervals, HMPV Human metapneumovirus
a. Admissions under 5 years of age; b. Cases of severe or very severe pneumonia amongst the admissions [29]; c. Samples eligible for testing from the pneumonia
admissions included only residents from within the Kilifi Health and Demographic Surveillance System (KHDSS) for years 2007–9, and residents or non-residents
for other years
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HMPV subgroup prevalence and dominance in Kilifi
was compared to other countries around the world. This
was based on analysis of 714 F gene sequences from 18
different countries and 500 G gene sequences from 15
countries retrieved from GenBank (Additional file 2).
General agreement in subgroup prevalence patterns was
observed for Kilifi and global data sets, the predomin-
ance of A2b and B2 in 2007–2010 and subsequent rise
of B1 and A2c in years that followed, Fig. 4. Notably, at
finer levels there were differences in subgroup temporal
occurrence. Globally, clades A2b, A2c and subgroup B1
persisted over the 9 years. In contrast, in Kilifi only sub-
group B2 persisted over the 9 years. The dominance of
B1 strains in 2011 was also evident globally. A1 and A2a
were the least commonly detected subgroups globally
and not observed in Kilifi.
Phylogenetic analysis of Kilifi HMPV viruses
Based on maximum likelihood phylogenies of F and G
genes, sequences from consecutive epidemics largely
clustered together. However, across multiple epidemics
sequences from the earlier years clustered together away
from those in recent years, Figs. 5 and 6. Further ana-
lysis of G gene sequences aligned temporally, revealed
circulation of multiple variants of a single subgroup in a
single epidemic year (see Additional files 4 and 5). Each
variant differed by at least five nucleotides (Additional
Fig. 1 A ML phylogenetic tree of 600 Gene sequences constructed using Kilifi sequences and sequences obtained from GenBank, collected from 2007 to
2016. Sequences were subtyped using references sequences retrieved from GenBank. Reference sequences colored in red. The numbers next to branches
indicate the bootstrap values. Subgroups were confirmed if sequences clustered with the reference sequences within a major branch with > 70% bootstrap
support. Taxa colored in magenta represent strains that have 180 nucleotide duplications retrieved from GenBank. Kilifi sequences are colored in brown
Table 2 HMPV positives stratified by age of patients admitted
to Kilifi County Hospital, Kenya 2007–2016
Age Categories Frequency Percent
0-2 M 51 18.61
3-5 M 67 24.45
6-8 M 43 15.69
9-11 M 35 12.77
12-17 M 20 7.30
18–23 20 7.30
25-35 M 27 9.85
36 +M 11 4.01
Total 274 100
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files 4 and 5) and clustered into separate clades, Fig. 6.
In comparison to contemporaneous viruses (714 F gene
sequences and 500 G gene sequences) (Additional file 2),
viruses from Kilifi and those from other locations were
highly similar, with an average nucleotide identity of
97.1 and 95.6% (in F gene), and 90.4 and 85.9% (in G
gene) for groups A and B, respectively. In phylogenies of
F and G, combining contemporaneous and Kilifi
Fig. 2 A ML phylogenetic tree of 563 unique F Gene sequences constructed using Kilifi sequences and sequences obtained from GenBank,
collected from 2007 to 2016. Sequences were subtyped using references sequences retrieved from GenBank. Reference sequences colored in red.
The numbers next to branches indicate the bootstrap values. Subgroups were confirmed if sequences clustered with the reference sequences
within a major branch with > 70% bootstrap support. Taxa colored in blue represent sequences of previously reported unique sub-lineage of A2,
retrieved from GenBank. Kilifi sequences are colored in brown
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sequence data, the Kilifi sequences did not cluster separ-
ately from others but interspersed with sequences from
Canada, Spain, Malaysia, Japan, USA, India and Croatia
(Figs. 1 and 2), and similarly, those viruses collected
from earlier years in Kilifi clustered away from those in
recent years.
F gene sequence analysis
Due to partial gene sequencing (345 bp) of the previ-
ously reported F gene Kilifi sequences retrieved from
GenBank [28], combined Kilifi sequences were trimmed
to 345 bp. The F gene sequences were highly conserved
both at the nucleotide (nt) and amino acid (aa) level with
Fig. 3 Temporal distribution of HMPV cases identified monthly from surveillance of severe and very severe pneumonia cases aged under 5 years
admitted to Kilifi County Hospital, Kenya 2007–2016. Number pneumonia cases and number tested are shown on the secondary Y axis and HMPV
cases detected shown on the primary Y axis. Samples eligible for testing from the pneumonia admissions included only residents from within the
Kilifi Health and Demographic Surveillance System (KHDSS) for years 2007–9, and residents or non-residents for other years
A B
C
Fig. 4 HMPV subgroup prevalence patterns Kilifi versus Global from 2007 to 2016. Panel a, Kilifi subgroup temporal patterns derived from Kilifi
sequence data determined by calendar year. Panel b, Kilifi subgroup temporal patterns determined by epidemic year. Panel c, global subgroup
temporal patterns determined from combined 714 F sequences and 500 G sequences retrieved from GenBank
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overall mean sequence identity of 89% (nt) and 97% (aa).
Within the individual subgroups, the nucleotide and
amino acid sequences were more conserved: there was
100% aa sequence similarity within clades A2b, A2c and
subgroup B1, and 99.9% within B2 subgroup, and the
mean nucleotide identities were 98.2% within B1, 99.2%
within A2c, 98.3% within both A2b and B2. The evolu-
tionary rates for F gene were estimated at 1.220× 10− 3
(95% highest posterior density (HPD) = 1.317× 10− 3 to
5.518× 10− 3), 1.857× 10− 3 (95% HPD = 1.111× 10–3 to
2.289× 10− 3), 1.242× 10− 3 (95%HPD = 8.303× 10− 4 to
1.689× 10− 3) and 1.050× 10− 3 (95%HPD = 5.937× 10− 4
to 1.600× 10− 3), nucleotide substitutions/site/year for
A2c, A2b, B1 and B2, respectively. Selection pressure
analysis of the F gene showed overall mean dN/dS ra-
tio of ω = 0.10, ω = 0.15, ω = 0.01 and ω = 0.12 for
A2c, A2b, B1 and B2, respectively (see Additional file
6). Using M2a and M3 models, no codon sites were
identified as positively selected among the four types
(sub-lineage A2b, sub-lineage A2c, B1 and B2 sub-
groups). (Additional file 6).
G gene sequence analysis (Kilifi)
G gene sequences were less conserved compared to F
gene sequences with overall mean sequence identity of
73% (nt) and 56% (aa). However, within subgroups
the sequences were highly conserved: the mean iden-
tities were estimated at 97% (nt) and 96% (aa) for
clade A2c, 93% (nt) and 89% (aa) for clade A2b, 94%
(nt) and 90% (aa) for B1, 92%(nt) and 87% for B2
subgroups. The deduced G gene amino acid se-
quences differed in lengths among subgroups: clade
A2c (220aa), clade A2b (218 and 229aa), B2 (238aa)
and B1 (232 and 242aa) long. The varying protein
lengths for clade A2b and B1 subgroups were due to
changes in stop codon positions. The evolutionary
rates for the G gene were estimated at 3.420× 10− 3
(95% HPD interval = 1.317× 10− 3 to 5.518× 10− 3),
8.022× 10− 3 (95% HPD = 5.893× 10− 3 to 1.060× 10− 2)
and 9.570× 10− 3 (95% HPD = 5.911× 10− 3 to 1.33×
10− 2) nucleotide substitutions/site/year for A2c, A2b
and B1, respectively. Evolutionary rate estimates for
subgroup B2 viruses were not determined, effective
sample size (ESS) for all parameters failed to reach
the cut-off (200) required for confirmation of conver-
gence in BEAST analysis. Among all the subgroups,
A2c exhibited significantly lower substitution rates
within the G gene (95% HPD = 1.317× 10− 3 to 5.518×
10− 3). The estimated times of the most common an-
cestor of the individual subgroups dated to recent
Fig. 5 ML phylogenies by subgroup for F gene Kilifi sequences colored by epidemic, from 2007 to 2016. The numbers next to branches indicate
the bootstrap values, a branch with > 70% bootstrap value was considered as a major branch
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origin in both F and G genes, i.e., 2009 (95% HPD =
2005–2011) for clade A2c sequences, 2008 (95%
HPD = 2006–2009) for clade A2b, 2005 (95% HPD =
2002–2007) for B1 and 2001(95% HPD = 1997–2005)
for B2 sequences. The estimated mean dN/dS ratio
(ω) was < 1 for A2b (ω = 0.57), A2c (ω = 0.38) and
B1(ω = 0.78). For the subgroup B2, a higher average
dN/dS ratio (ω = 1.21) was determined for G gene, in-
dicating a signal of positive selection (Additional file
6). Using M2a and M3 models, 3 positively selected
sites were identified within A2c (17, 24, 28, and) and
A2b (87, 123 and 135), 1 site (96) in B1 and 2 sites
(12,127) within B2 sequences (Additional file 6).
HMPV subgroup and disease severity
We did not observe a statistically significant association
between HMPV subgroup and pneumonia severity ( p-
value = 0.264) (Table 3).
Discussion
There remains limited information on long-term circula-
tion patterns and prevalence of HMPV in Africa. This
study reports HMPV subtype incidence and molecular
evolution in coastal Kenya over a 10-year period of sur-
veillance (2007 to 2016). HMPV incidence in children
under 5 years of age varied annually ranging from 1.2 to
8.7% and 71.5% of HMPV infections were in children
Fig. 6 ML phylogenies by subgroup for G gene Kilifi sequences colored by epidemic, from 2007 to 2016. The numbers next to branches indicate
the bootstrap values, a branch with > 70% bootstrap value was considered as a major branch. Different variants observed within an epidemic are
indicated next to branches colored by epidemic year. Cut off > = 70% bootstrap support was considered significant for variant assignment. The
nucleotide differences between the variants are shown in Additional files 4 and 5
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aged < 2 years. Wide variation in annual prevalence has
been reported elsewhere from long-term studies of acute
respiratory infection (ARI) aetiology in children: in
Germany, HMPV prevalence over 10 years of surveil-
lance varied between 1.4 and 32.8% [21], and in Italy,
the prevalence fluctuated from 37 to 7% and then to
43% over a 3 year period [24]. To date the cause of the
varied prevalence and whether there is difference in
disease severity among HMPV subgroups remains un-
clear. Different studies report contrasting results on the
association of disease severity among the HMPV sub-
groups [10, 40]. In this study, no significant association
was found between subgroup and disease severity or
clinical presentation. Further studies are necessary to
evaluate whether changes in subgroup are associated
with changes in disease severity and prevalence. Climatic
factors such as temperature, rainfall and relative humid-
ity have also been shown to influence HMPV activity in
the tropics [23]. In this study, seasonal increase in cases
tended to coincide with low rainfall, lower relative hu-
midity and higher temperatures. Further investigation is
required to determine whether changes in such environ-
mental factors influence HMPV activity.
Kilifi HMPV subgroup prevalence patterns partly mir-
rored global patterns, there was predominance of A2b
and B2 in 2007–2010 and subsequent rise of B1 and A2c
in years that followed. B2 viruses persisted over the 9
years. A1 and A2a were the least commonly detected
subgroups globally and this could probably explain why
they were not detected in Kilifi. In contrast to continued
circulation of clade A2b [18], in Kilifi, A2b circulated
from 2007 to November 2012 and no longer. Occur-
rence of the clade A2c [41] has increased in Kilifi in re-
cent years, as similarly reported in Bangladesh and
Croatia [15, 16], suggestive of global spread of HMPV
variants. Based on F and G phylogenies, some of previ-
ously reported sequences from Europe, Asia and USA
that either had not been sub-grouped or assigned to
clade A2b, clustered within A2c, consistent with findings
from a previous report [15]. Similarly, previously re-
ported sequences of the unique A2 clade reported in
Malaysia [23] also clustered in this clade (A2c). Recently,
two novel HMPV A2 strains with 180 or 111 nucleotide
duplication in the G gene have also been reported [17,
20]. These strains were not observed in Kilifi. In the
phylogenetic trees they clustered within A2c together
with other A2c sequences without duplication including
Kilifi A2c strains. Our findings reaffirm the circulation
of A2c clade and point out the need for proper methods
for classification of HMPV lineages. The replacement
patterns of HMPV subgroups could be attributed to sub-
group-specific herd immunity offering protection against
circulating homologous strains but not against heterol-
ogous strains. This observation is not unique to Kilifi, as
similar patterns were reported from long-term surveil-
lance studies in Germany and France [21, 42]. Consist-
ent with earlier studies, G gene exhibited higher rates of
evolution compared to F gene [2]. F gene is more con-
served and our findings concur with previous studies on
F protein diversity [43]. The rates of G gene evolution
were in the range of 3.42× 10− 3 to 9.57× 10− 3, similar to
findings from previous studies [44, 45]. Among the sub-
groups, the rates of evolution for A2b and B1 were at
least 2 fold higher than other subgroups, this concurs
with the findings from a similar study [44]. In general,
higher polymorphism has been reported in HMPV G
gene and further within the subgroups resulting from
events such as changes in alternative transcription ter-
mination codons and insertions [46]. This could explain
the differences in evolution rates. Further investigations
are required to give more insights on the differences in
evolution rates and its implication. Compared to other
Pneumoviruses, such as human respiratory syncytial
virus (HRSV), HMPV G gene has been shown to have
higher rates of evolution [45]. Our estimates show com-
parable results, the rates for HMPV A2b and B1 were 3
to 4 times higher than those reported for HRSV (3.58×
10− 3, 95% HPD = 3.04× 10− 3 to 4.16× 10− 3) [47]. The
difference in the rates of evolution can be linked to
strong association between neutralizing epitopes and
positively selected sites reported for RSV G gene [48]. In
contrast to the case for other paramyxoviruses, such as
RSV, the HMPV G protein is not a major neutralizing or
protective antigen [49].
Temporal analysis revealed circulation of multiple sub-
groups within a single epidemic. Further analysis of the G
glycoprotein encoding gene revealed circulation of mul-
tiple variants for a single subgroup within an epidemic.
Table 3 Association between different HMPV subgroups and
disease severity
Subgroup WHO Pneumonia Status Total
Severe Very severe
A2b n 71 13 84
% 84.52 15.48 100
A2c n 20 2 22
% 90.91 9.09 100
B1 n 35 13 48
% 72.92 27.08 100
B2 n 41 10 51
% 80.39 19.61 100
n
Total % 167 38 205
81.46 18.54 100
p-value = 0.264
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Multiple variants observed might be attributed to high
rate of G gene evolution (substitutions/site/year) resulting
in diversification in situ during a season. However, the
level of variation observed within a subgroup within epi-
demics was greater that would be expected from in situ di-
versification, implying multiple variant introductions of a
subgroup during single epidemic years.
As is the norm for HMPV detection in respiratory
samples, we used molecular PCR-based diagnostics [6].
Recent studies have shown that mutations at primer and
probe binding sites can lead to false negative diagnostic
results and hence underestimation of disease burden [50,
51]. Evaluation of the in-house diagnostic rRT-PCR
assay would be important to determine whether there
are any missed variants/subgroups and whether this can
be associated with the apparent gradual decline in
HMPV prevalence observed in the current dataset.
There is also some evidence that reduction in bacterial
pneumonia (e.g. S. pneumoniae), as has been seen in this
coastal location over this study period [52], results in a
reduction in viral pneumonia [53, 54]. Future investiga-
tions will be necessary to give more insight.
The analysed Kilifi F and G protein encoding genes
were generally determined to be under purifying selec-
tion pressure, which drives RNA virus evolution by puri-
fying the deleterious mutations due to RNA replication
errors [55]. However, for the B2 subgroup, a higher dN/
dS ratio was observed in G gene sequences suggestive of
diversifying selection within B2 viruses. The distinct di-
versifying selection and persistence of the B2 viruses ob-
served requires further investigation. In this study, our F
and G genes sequence analyses were based on partial
gene lengths, 345 bp and 640 bp, respectively. Therefore,
our results on the genetic distance estimates, evolution-
ary and selection pressure analysis should be interpreted
with caution. The partial lengths may have reduced our
potential to discriminate genetic clusters, a possible ex-
planation for higher sequence similarity observed be-
tween and within the subgroups for F gene. Overall,
although our sequence analyses were limited to partial
lengths, the newly designed F and G genes primers
allowed full length sequencing of the two genes for
newly generated data. In addition, the newly designed G
gene subtype specific primers allowed sequencing of all
HMPV subtypes and significantly improved G PCR re-
covery by two-fold compared to previously reported
assay. This improved the study power to characterise the
different circulating HMPV variants. Overall, we suc-
cessfully collected clinical samples from 74% (6756/
9076) of the study enrolled participants and charac-
terised 75% (205/274) of the HMPV viruses identified. In
this study we failed to collect samples from 24% of the
eligibles. We have previously reported similar results,
which results from refusals and difficulty in collection of
nasal specimens from children with very severe disease
[29]. Hence, if some HMPV variants are associated with
disease severity there may be bias in the prevalence and
variant composition estimates. However, the proportion
not collected shows no systematic change over time. In
addition, the proportion of very severe pneumonia
cases was high among sampled eligibles compared to
unsampled eligibles. Therefore, it’s unlikely there was
any bias in the prevalence estimates of HMPV groups
or subgroups.
Our analyses on HMPV epidemiology in Kilifi were
limited to two viral genes only. Whole genome sequen-
cing might give more insights into transmission, HMPV
subgroup characterisation and molecular evolution. Our
estimation and inference on the association between
HMPV subgroup and disease severity was biased to in-
patient surveillance data, and therefore future studies
should include outpatient surveillance data. In addition,
inpatient surveillance and sampling of HMPV infections
might not be representative of the full variant population
circulating in this community and not correctly reflect
incidence and prevalence, as HMPV infections have also
been reported in outpatient settings [56]. Future studies
across different locations in Kenya and in Africa will be
important for tracing the introduction and transmission
patterns of the virus.
Conclusions
In conclusion, this report shows HMPV activity charac-
terised by marked annual variation in occurrence, and in
subgroup prevalence patterns (reflecting those in other
locations globally,) gradual replacement of subgroups
over time, and multiple circulating variants each epi-
demic varying year to year. This suggests, widescale and
rapid circulation of HMPV subgroups, seasonal epi-
demics resulting from multiple introductions rather than
single source, and possible evidence of herd immunity
replacement at the subgroup and within-subgroup clus-
ter level.
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